← Home / Editas Medicine, Inc. (EDIT)
Stock Analysis
Editas Medicine, Inc. (EDIT)
EDIT
EDIT · Market data
2.87 -1.03%
Track EDIT in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when EDIT price is:
52W Range Position
48%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-09 19:41 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 2.87. Holding above 2.72 keeps the current thesis intact.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
2.72
↗
Break Above
Confirmation improves above resistance.
2.87
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 2.72
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
5
●
Financial Results
HIGH
EDIT reports financial results
On August 3, 2026, Elliott Levy, M.D., a member of the Board of Directors (the “Board”) of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026.
8-K Filing • SEC EDGAR
AUG
5
●
Management / Board
HIGH
EDIT board and management update
On August 3, 2026, Elliott Levy, M.D., a member of the Board of Directors (the “Board”) of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026.
8-K Filing • SEC EDGAR
MAY
26
●
Material Agreement
MEDIUM
EDIT material agreement
Public Offering On May 26, 2026, Editas Medicine, Inc.
8-K Filing • SEC EDGAR
What's Driving EDIT?
📈 Technical recovery is improving
Momentum is Neutral. Watch 2.87 for confirmation and 2.72 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 2.72 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
Pattern
Triangle Compression
State
Forming
Compression
15%
RSI(14)
50.9
◎
How to read this setup
The nearest decision zone is framed by support around 2.72 and resistance near 2.87. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
EDIT — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-07
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$280.9M
Company size
EV
$254.6M
Debt-adjusted value
P/E
-2.6
Not meaningful
P/S
7.3
Balanced
P/B
63.7
Very high
EV/Sales
6.6
Balanced
EV/EBIT
-2.3
Not meaningful
P/FCF
-2.0
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Recovering
⚖
Balance Sheet
Manageable
💵 Revenue
2.83M
↘ Weak
📈 Net Income
-24.98M
↘ Negative
🧮 EPS (Basic)
-0.26
↘ Negative
Editas Medicine, Inc.
Related Opportunities